חוב לטווח ארוך של החברה: Lexeo Therapeutics (LXEO)

Lexeo Therapeutics (LXEO) is developing gene therapy methods for the heart, optimizing international trials to protect profits and supply chains. This price chart shows Lexeo Therapeutics (LXEO) shares with long-term debt at 0.01, while the biotech's success depends on gene delivery safety and regulatory approvals. Looking ahead, the company plans to expand its pipeline of drugs for cardiopathies and Alzheimer's disease, safeguarding its unique vectors.

Long-term debt determines the level of a business's credit burden, impacting the final net income. Assessing a company's long-term borrowed capital allows for the identification of critical over-leverage points. This indicator aggregates all liabilities with a maturity of more than one year, measuring the financial stability of the structure. For Lexeo Therapeutics (LXEO), this metric is critical, as a high dependence on clinical trial outcomes makes debt servicing risky.